

Refine Search

Search Results -

Terms	Documents
L1 with L2	67

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L3

Search History

DATE: Thursday, October 27, 2005 [Printable Copy](#) [Create Case](#)

<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
side by side			
<i>DB=PGPB,USPT; PLUR=YES; OP=AND</i>			
<u>L3</u>	l1 with L2	67	<u>L3</u>
<u>L2</u>	fibrotic adj disorder or (hepatic or pulmonary or renal or heart or skin) adj fibrosis or keloid or hypertrophic adj scar	7937	<u>L2</u>
<u>L1</u>	adenoviral adj vector or adenovirus	37470	<u>L1</u>

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 20 of 67 returned.**

-
- ☐ 1. [20050201984](#). 24 Feb 05. 15 Sep 05. Recombinant adenoviral vectors and their utility in the treatment of various types of fibrosis: hepatic, renal, pulmonary, as well as hypertrophic scars. Armendariz Borunda, Juan, et al. 424/93.2; 435/235.1 435/456 A61K048/00 C12N015/861 C12N007/00.
-
- ☐ 2. [20050119275](#). 17 Jun 04. 02 Jun 05. Salt and crystal forms of (5-chloro-2-{2-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-- dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-methanesulfonic acid. Berliner, Martin A., et al. 514/255.01; 544/386 A61K031/495 C07D241/04.
-
- ☐ 3. [20050090501](#). 31 May 01. 28 Apr 05. Heteroaryl-cyclic acetals. Collis, Alan, et al. 514/252.01; 514/255.05 514/256 514/339 544/238 544/333 544/405 546/282.4 C07D045/04 A61K031/506 A61K031/501 A61K031/497.
-
- ☐ 4. [20050063944](#). 19 Sep 03. 24 Mar 05. Method of inducing maturation of dendritic cells and uses therefor. Li, Jian, et al. 424/85.1; 424/85.2 A61K038/19 A61K038/20.
-
- ☐ 5. [20050009876](#). 19 Nov 03. 13 Jan 05. Indazole compounds, compositions thereof and methods of treatment therewith. Bhagwat, Shripad S., et al. 514/338; 514/406 546/275.7 548/361.1 A61K031/4439 A61K031/4162 C07D43/02.
-
- ☐ 6. [20050009831](#). 18 Mar 04. 13 Jan 05. Chemical compounds. Ratcliffe, Andrew James, et al. 514/249; 544/349 A61K031/498 C07D487/04.
-
- ☐ 7. [20050008638](#). 25 Jun 03. 13 Jan 05. CNGH0005 polypeptides, antibodies, compositions, methods and uses. Lu, Jin, et al. 424/145.1; 435/183 435/320.1 435/325 435/6 435/69.1 530/388.26 536/23.2 C12Q001/68 C07H021/04 A61K039/395 C12N009/00 C07K016/40 C12P021/02 C12N005/06.
-
- ☐ 8. [20040259914](#). 10 Jun 04. 23 Dec 04. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity. Ko, Soo S., et al. 514/317; 514/326 546/207 546/231 A61K031/445 C07D41/02 C07D211/28.
-
- ☐ 9. [20040259783](#). 09 Aug 04. 23 Dec 04. Pharmaceutical compositions of marine sponge microciona prolifera. Cruz, Tony, et al. 514/12; 530/350 A61K038/17 C07K014/47.
-
- ☐ 10. [20040248837](#). 29 Oct 03. 09 Dec 04. Methods of treating pulmonary fibrotic disorders. Raz, Eyal, et al. 514/44; A61K048/00.
-
- ☐ 11. [20040248260](#). 27 Feb 04. 09 Dec 04. IL-13 mutein proteins, antibodies, compositions, methods and uses. Heavner, George A., et al. 435/69.5; 435/320.1 435/325 530/351 536/23.5 C07K014/54 C07H021/04 C12P021/02.
-
- ☐ 12. [20040219137](#). 28 May 04. 04 Nov 04. Method for reducing exacerbations associated with COPD. Edelson, Jeffrey D.. 424/94.1; 435/183 A61K038/43 C12N009/00.
-
- ☐ 13. [20040209868](#). 11 May 04. 21 Oct 04. Substituted indoles. Ritzeler, Olaf, et al. 514/217.08; 514/323 514/414 540/602 546/201 548/465 A61K031/55 A61K031/454 A61K031/405 C07D43/02.
-
- ☐ 14. [20040185450](#). 21 Mar 03. 23 Sep 04. MCP-1 mutant proteins, antibodies, compositions, methods and uses. Heavner, George A., et al. 435/6; 435/320.1 435/325 435/69.1 530/350 536/23.5 C12Q001/68 C07H021/04 C07K014/74.
-
- ☐ 15. [20040156827](#). 01 Dec 03. 12 Aug 04. Recombinant adenoviral vectors and their utility in the treatment

of various types of fibrosis: hepatic, renal, pulmonary, as well as hypertrophic scars. Armendariz Borunda, Juan, et al. 424/93.2; 435/456 A61K048/00 C12N015/861.

☐ 16. 20040120956. 25 Jun 03. 24 Jun 04. CNGH0004 polypeptides, antibodies, compositions, methods and uses. Song, Xiao-Yu R., et al. 424/146.1; 435/226 435/320.1 435/325 435/6 435/69.1 530/387.2 530/388.26 536/23.2 C12Q001/68 C07H021/04 A61K039/395 C12N009/64.

☐ 17. 20040116441. 16 Oct 03. 17 Jun 04. Methods of using sulfonic acid derivatives. Brown, Matthew F., et al. 514/252.13; 514/255.01 A61K031/495 A61K031/496.

☐ 18. 20040110759. 28 Jul 03. 10 Jun 04. Substituted beta carbolines. Ritzeler, Olaf, et al. 514/248; 514/250 514/267 514/292 544/234 544/251 544/345 546/82 A61K031/519 A61K031/503 A61K031/498 A61K031/4745 C07D487/14.

☐ 19. 20040097554. 16 Oct 03. 20 May 04. Heteroaryl-hexanoic acid amide derivatives as immunomodulatory agents. Brown, Matthew F., et al. 514/340; 514/355 514/422 514/423 546/268.1 546/315 548/517 548/537 A61K031/4439 A61K031/455 A61K031/4025 A61K031/401 C07D43/02.

☐ 20. 20040097455. 24 Oct 03. 20 May 04. Recombinant viral and non-viral vectors containing the human urokinase plasminogen activator gene and its utilization in the treatment of various types of hepatic, pulmonary, pancreatic and cardiac fibrosis and hypertrophic scars. Borunda, Juan Armendariz, et al. 514/44; A61K048/00.

[Generate Collection](#)[Print](#)

Terms	Documents
L1 with L2	67

[Prev Page](#)[Next Page](#)[Go to Doc#](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 21 through 40 of 67 returned.**

-
- ☐ 21. [20040092529](#). 16 Oct 03. 13 May 04. Methods of using piperazine derivatives. Blumberg, Laura C., et al. 514/255.01; A61K031/495.
-
- ☐ 22. [20040087571](#). 16 Oct 03. 06 May 04. Methods of using CCR1 antagonists as immunomodulatory agents. Brown, Matthew F., et al. 514/210.17; 514/246 514/247 514/255.06 514/256 514/354 514/423 A61K031/397 A61K031/53 A61K031/50 A61K031/4965 A61K031/505.
-
- ☐ 23. [20040038991](#). 13 May 03. 26 Feb 04. Imidazolyl-cyclic acetals. Bamborough, Paul L., et al. 514/256; 514/341 544/324 546/272.7 A61K031/506 A61K031/4439 C07D45/14.
-
- ☐ 24. [20040023338](#). 24 Oct 02. 05 Feb 04. IL-4 mutein proteins, antibodies, compositions, methods and uses. Heavner, George A., et al. 435/69.52; 435/320.1 435/325 530/351 530/388.23 536/23.5 C07H021/04 C12P021/04 C07K014/54 C12P021/02 C12N005/06.
-
- ☐ 25. [20040023337](#). 25 Oct 02. 05 Feb 04. IL-13 mutein proteins, antibodies, compositions, methods and uses. Heavner, George A., et al. 435/69.52; 435/320.1 435/325 530/351 536/23.5 C07K014/54 C07H021/04 C12P021/04 C12N005/06.
-
- ☐ 26. [20040023336](#). 25 Oct 02. 05 Feb 04. Mut-IL-18 or Mut-IL-18R proteins, antibodies, compositions, methods and uses. Heavner, George A., et al. 435/69.52; 435/320.1 435/325 530/351 536/23.5 C07H021/04 C12P021/04 C12P021/02 C12N005/06 C07K014/54.
-
- ☐ 27. [20040019022](#). 18 Jul 03. 29 Jan 04. Use of 2,3 alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction, damage and injury in mammals. Stec, Karen, et al. 514/159; 514/192 514/2 514/252.13 514/253.08 514/29 514/312 514/34 514/8 A61K038/12 A61K038/00 A61K038/16 A61K031/704 A61K031/60 A61K031/496.
-
- ☐ 28. [20040005995](#). 27 Jan 03. 08 Jan 04. Method for reducing exacerbations associated with copd. Edelson, Jeffrey D. 514/1; A61K031/00.
-
- ☐ 29. [20030211152](#). 12 Jun 03. 13 Nov 03. Controlled release formulation for treating COPD. Faulkner, Patrick G., et al. 424/468; 514/521 A61K009/22 A61K031/277.
-
- ☐ 30. [20030207901](#). 14 May 03. 06 Nov 03. Hydroxyl-containing compounds. Underiner, Gail E., et al. 514/263.36; 514/251 514/266.3 514/308 514/415 A61K031/525 A61K031/522 A61K031/517 A61K031/47 A61K031/4035.
-
- ☐ 31. [20030119820](#). 04 Oct 02. 26 Jun 03. Substituted indoles. Ritzeler, Olaf, et al. 514/217.08; 514/323 514/414 514/421 540/602 546/209 548/465 548/484 A61K031/55 A61K031/404 A61K031/454 C07D43/02 C07D209/36.
-
- ☐ 32. [20030113816](#). 18 Sep 02. 19 Jun 03. Methods of assaying connective tissue growth factor. Weitz, Stephen L., et al. 435/7.9; 435/7.92 G01N033/53 G01N033/542 G01N033/537 G01N033/543.
-
- ☐ 33. [20030092101](#). 16 Jan 02. 15 May 03. Human tumor necrosis factor receptors TR13 and TR14. Ni, Jian, et al. 435/69.1; 435/320.1 435/325 530/350 536/23.5 C07K014/715 C07H021/04 C12P021/02 C12N005/06.
-
- ☐ 34. [20030003077](#). 18 Mar 02. 02 Jan 03. Recombinant adenoviral vectors and their utility in the treatment of various types of fibrosis: hepatic, renal, pulmonary, as well as hypertrophic scars. Armendariz Borunda,

Juan, et al. 424/93.2; 435/235.1 435/320.1 435/456 A61K048/00 C12N007/00 C12N015/861.

☐ 35. 20020142415. 23 Mar 01. 03 Oct 02. Novel polypeptides and polynucleotides and methods of using them. Koopman, Peter Anthony, et al. 435/183; 435/320.1 435/325 435/6 435/69.1 530/350 536/23.2 C12Q001/68 C07H021/04 C12N009/00 C12P021/02 C12N005/06 C07K014/435.

☐ 36. 20020099068. 15 Mar 01. 25 Jul 02. Substituted beta carbolines. Ritzeler, Olaf, et al. 514/292; 546/87 A61K031/4745 C07D471/04.

☐ 37. 20010039048. 01 Feb 01. 08 Nov 01. Recombinant adenovirus and its use for the prevention and treatment of fibrotic disease. Wu, Chu-Tse, et al. 435/325; 424/233.1 435/235.1 435/320.1 530/350 C12N007/01 C12N007/00 A61K039/23 C07K001/00.

☐ 38. 6951738. 16 Jan 02; 04 Oct 05. Human tumor necrosis factor receptors TR13 and TR14. Ni, Jian, et al. 435/69.1; 435/252.3 435/320.1 435/325 435/455 530/350 536/23.5. C12N015/09 C07H021/04.

☐ 39. 6713509. 22 Aug 01; 30 Mar 04. Controlled release formulation for treating COPD. Faulkner, Patrick G., et al. 514/520; 424/457 424/458 424/462 424/468 424/469 424/470 424/486 424/487 424/490 424/497 514/522 514/523 514/524 514/525 514/826. A61K031/275.

☐ 40. 6693105. 27 Jul 99; 17 Feb 04. Hydroxyl-containing compounds. Underiner, Gail E., et al. 514/263.3; 436/98 514/263.2 544/267. A61K031/522 C07D473/00 G01N033/00.

Generate Collection

Print

Terms	Documents
L1 with L2	67

[Prev Page](#)

[Next Page](#)

[Go to Doc#](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 41 through 60 of 67 returned.**

-
- ☐ 41. [6627637](#). 15 Mar 01; 30 Sep 03. Substituted beta carbolines. Ritzeler; Olaf, et al. 514/292; 514/232.8 544/126 546/81. C07D471/02 A61K031/44.
-
- ☐ 42. [6218406](#). 02 Jul 99; 17 Apr 01. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments. Bourzat; Jean-Dominique, et al. 514/339; 514/323 514/410 514/423 546/200 546/276.7 548/425. A61K031/4439 A61K031/403.
-
- ☐ 43. [6133274](#). 26 Nov 96; 17 Oct 00. Hydroxyl-containing bicyclic compounds. Underiner; Gail E., et al. 514/263.36; 544/267. C07D473/04 A61K031/52.
-
- ☐ 44. [6124465](#). 02 Jul 99; 26 Sep 00. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments. Bourzat; Jean-Dominique, et al. 546/276.7; 546/279.1 548/127 548/305.1 548/345.1 548/414 548/419 548/425. C07D401/08 C07D209/56 C07D209/80 C07D233/56 C07F009/28.
-
- ☐ 45. [6121270](#). 17 Jun 98; 19 Sep 00. Epoxide-containing compounds. Underiner; Gail, et al. 514/263.23; 544/263. A61K031/52 C07D473/04.
-
- ☐ 46. [6103730](#). 07 Jun 95; 15 Aug 00. Amine substituted compounds. Klein; J. Peter, et al. 514/263.2; 514/151 514/210.21 514/263.21 514/263.22 514/263.23 514/263.24 514/263.35 544/268 544/269 544/270 544/271 544/272. A61K031/522 C07D473/10.
-
- ☐ 47. [6100271](#). 07 Jun 95; 08 Aug 00. Therapeutic compounds containing xanthinyl. Klein; J. Peter, et al. 514/263.2; 514/210.21 514/234.2 514/263.22 514/263.23 514/263.24 514/263.35 544/268 544/269 544/271. A61K031/522 C07D473/10.
-
- ☐ 48. [6043250](#). 07 Jun 95; 28 Mar 00. Methods for using therapeutic compounds containing xanthinyl. Klein; J. Peter, et al. 514/234.2; 514/210.21 514/263.2 514/263.22 514/263.23 514/263.35. A61K003/52.
-
- ☐ 49. [6013662](#). 29 Dec 97; 11 Jan 00. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments. Bourzat; Jean-Dominique, et al. 514/410; 546/276.7 548/127 548/305.1 548/345.1 548/425. A01N043/38 C07D209/56 C07D235/08 C07D401/08.
-
- ☐ 50. [5889011](#). 27 Jun 97; 30 Mar 99. Substituted amino alkyl compounds. Klein; J. Peter, et al. 514/263.35; 544/264 544/265 544/267. C07D473/00 A61K031/52.
-
- ☐ 51. [5866576](#). 03 Jan 97; 02 Feb 99. Epoxide-containing compounds. Underiner; Gail, et al. 514/256; 514/262.1 514/263.23 514/396 544/242 548/300.1 548/311.1. A61K031/505 C07D239/02.
-
- ☐ 52. [5837703](#). 12 Nov 93; 17 Nov 98. Amino-alcohol substituted cyclic compounds. Kumar; Anil M., et al. 514/183; 514/211.15 514/228.8 514/241 514/242 514/249 514/256 514/266.2 514/266.3 514/270 514/274 514/309 514/312 514/315 514/348 514/357 514/374 514/400 514/425 514/427 540/467 540/544 544/216 544/257 544/272 544/286 544/301 544/311 544/335 546/1 41 546/142 546/157 546/246 546/296 546/334 546/96 548/215 548/340.1 548/485 548/546 548/561. A61K031/55 A61K031/515 A61K031/445 A61K031/52.
-
- ☐ 53. [5824677](#). 07 Jun 95; 20 Oct 98. Substituted amino alcohol compounds. Klein; J. Peter, et al. 514/222.5; 514/223.5 514/224.5 514/226.8 514/227.5 514/228.8 514/229.2 514/230.5 514/230.8 514/237.8 514/248 514/249 514/255.02 514/260.1 514/274 514/301 514/303 514/311 514/351 514/360 514/361 514/362 514/363 514/364 514/365 514/367 514/372 514/3 73 514/374 514/375 514/376 514/378 514/379 514/380

514/387 514/395 514/415 514/418 514/424 514/425 514/432 514/433 514/438 514/452 544/127 544/128
544/162 544/2 544/215 544/219 544/229 544/235 544/237 544/255 544/278 544/3 544/311 544/353 544/385
544/5 54 4/53 544/63 544/65 544/66 544/67 544/8 544/90 544/91 546/113 546/114 546/164 546/300 548/123
548/125 548/131 548/134 548/143 548/146 548/153 548/174 548/207 548/214 548/215 548/217 548/221
548/228 548/229 548/237 548/240 548/241 548/243 548/247 548/267.2 548/303.7 548/307.1 548/453 548/486
548/543 548/546 549/14 549/367 549/368 549/50 549/75. A61K031/385 A61K031/445 A61K031/47
A61K031/505.

☐ 54. 5817662. 06 Jun 95; 06 Oct 98. Substituted amino alkyl compounds. Klein; J. Peter, et al. 514/263.35;
424/824 424/825. A61K031/52.

☐ 55. 5807862. 07 Jun 95; 15 Sep 98. Therapeutic compounds containing pyrimidinyl moieties. Klein; J.
Peter, et al. 514/269; 544/309 544/310 544/311 544/312. A61K031/505 C07D239/54.

☐ 56. 5807861. 07 Jun 95; 15 Sep 98. Amine substituted xanthinyl compounds. Klein; J. Peter, et al.
514/263.35; 514/151 514/210.21 514/263.2 514/263.22 514/263.23 514/81. A61K031/52.

☐ 57. 5804584. 06 Jun 95; 08 Sep 98. Therapeutic compounds containing a monocyclic five- to six-
membered ring structure having one to two nitrogen atoms. Underiner; Gail E., et al. 514/269; 514/256 544/242
544/298 544/301 544/302. C07D239/54 A61K031/52.

☐ 58. 5801182. 07 Jun 95; 01 Sep 98. Amine substituted compounds. Klein; J. Peter, et al. 514/269; 514/274
544/310 544/311 544/312. A61K031/505 C07D239/02.

☐ 59. 5801181. 07 Jun 95; 01 Sep 98. Amino alcohol substituted cyclic compounds. Michnick; John, et al.
514/263.35; 514/183 514/249 514/266.3 514/274 514/309 514/315 514/418 514/425 514/617 514/619 514/626
514/668 514/669. A01N043/00 A01N043/90 A01N043/58 A01N043/42.

☐ 60. 5780476. 06 Jun 95; 14 Jul 98. Hydroxyl-containing xanthine compounds. Underiner; Gail E., et al.
514/263.36;. A61K031/52 C07D473/04.

Generate Collection

Print

Terms	Documents
L1 with L2	67

[Prev Page](#)

[Next Page](#)

[Go to Doc#](#)

Generate Collection

Print

Search Results - Record(s) 61 through 67 of 67 returned.

- ☐ 61. 5777117. 07 Jun 95; 07 Jul 98. Method for preparing substituted amino alcohol compounds. Klein; J. Peter, et al. 544/267; 544/257 544/285 544/286 544/287 544/311 546/141 546/243 546/246 548/477 548/546. C07D473/10 C07D239/80 C07D211/94 C07D209/48.
- ☐ 62. 5777115. 07 Feb 94; 07 Jul 98. Acetal-and ketal-substituted pyrimidine compounds. Leigh; Alistair, et al. 544/242; 544/267. C07D239/26 A61K031/505.
- ☐ 63. 5770595. 07 Feb 94; 23 Jun 98. Oxime substituted therapeutic compounds. Klein; J. Peter, et al. 514/263.35; 514/151 544/271 544/273. M61K031/52.
- ☐ 64. 5750575. 07 Jun 95; 12 May 98. Substituted amino alcohol compounds. Klein; J. Peter, et al. 514/617; 514/653 564/182 564/355 564/361. A61K031/165 A61K031/135 C07C233/35 C07C215/20.
- ☐ 65. 5670506. 05 Apr 93; 23 Sep 97. Halogen, isothiocyanate or azide substituted xanthines. Leigh; Alistair, et al. 514/141; 544/267 544/272 544/277. A61K031/52 C07D473/00.
- ☐ 66. 5641783. 08 Sep 94; 24 Jun 97. Substituted amino alcohol compounds. Klein; J. Peter, et al. 514/263.35; 514/183 514/222.5 514/223.5 514/224.2 514/226.8 514/227.5 514/228.8 514/229.2 514/230.5 514/230.8 514/237.8 514/241 514/242 514/243 514/246 514/247 514/248 514/249 514/252.16 514/256 514/259.5 514/264.1 514/266.3 514/270 514/274 514/29 7 514/300 514/301 514/302 514/303 514/306 514/307 514/311 514/312 514/315 514/345 514/351 514/357 514/359 514/360 514/361 514/362 514/363 514/364 514/365 514/367 514/369 514/372 514/373 514/374 514/375 514/376 514/378 514/379 514/380 514/381 514/383 514/3 89 514/394 514/395 514/398 514/399 514/401 514/404 514/406 514/413 514/415 514/416 514/418 514/423 514/424 514/425 514/427 514/428 544/1 544/162 544/2 544/215 544/216 544/219 544/220 544/224 544/235 544/239 544/254 544/255 544/257 544/262 544/272 544/277 544/278 544/280 544/283 544/286 544/3 544/301 544/311 544/335 544/336 544/350 544/353 544/385 544/401 544/53 544/63 544/65 544/66 544/67 544/8 544/90 544/91 546/102 546/113 546/114 546/115 546/117 546/118 546/119 546/122 546/138 546/139 546/150 546/153 54 6/157 546/164 546/176 546/178 546/242 546/243 546/246 546/264 546/300 546/334 548/100 548/123 548/125 548/127 548/128 548/131 548/134 548/146 548/153 548/179 548/186 548/207 548/214 548/215 548/217 548/221 548/225 548/228 548/229 548/235 548/237 548/240 5 48/241 548/243 548/247 548/252 548/267.2 548/267.8 548/303.7 548/306.4 548/307.1 548/309.7 548/319.1 548/323.5 548/340.1 548/348.1 548/349.1 548/356.1 548/370.1 548/375.1 548/379.4 548/452 548/453 548/470 548/482 548/485 548/486 548/491 548/503 548/532 54 8/543 548/546 548/550 548/565 548/566. A61K031/415 A61K031/42 A61K031/425 A61K031/52.
- ☐ 67. 5470878. 08 Dec 93; 28 Nov 95. Cell signaling inhibitors. Michnick; John, et al. 514/558; 514/274 514/299 514/315 514/418 514/425 514/529 514/552 514/561 514/613 514/617 514/626 514/629 514/669 544/254 544/285 544/301 546/183 546/243 548/486 548/556. A61K031/20 C07C233/00.

Generate Collection

Print

Terms	Documents
L1 with L2	67

[Prev Page](#)[Next Page](#)[Go to Doc#](#)